Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: Potentiation of morphine anti-allodynic activity by NOP receptor antagonists

The effect of new NOP receptor agonists and antagonists in the rat chronic constriction injury model was investigated. Intraperitoneally administered NOP receptor agonist SR14150 and antagonists SR16430 and SR14148, had no effect on mechanical allodynia when given alone. The nonselective NOP/mu-opio...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2009-05, Vol.610 (1), p.49-54
Main Authors: Khroyan, Taline V., Polgar, Willma E., Orduna, Juan, Jiang, Faming, Olsen, Cris, Toll, Lawrence, Zaveri, Nurulain T.
Format: Article
Language:English
Subjects:
Analgesics, Opioid - pharmacology
Analgesics, Opioid - therapeutic use
Animals
Biological and medical sciences
Chronic constriction injury
Chronic pain
Drug Evaluation, Preclinical
Drug Interactions
Indoles - pharmacology
Indoles - therapeutic use
Ligands
Male
Medical sciences
Mononeuropathies - drug therapy
Mononeuropathies - etiology
Morphine - pharmacology
N/OFQ
Neuropathy
NOP
NOP antagonist
Pain - drug therapy
Pain Measurement - methods
Pharmacology. Drug treatments
Phenalenes - pharmacology
Phenalenes - therapeutic use
Rats
Rats, Sprague-Dawley
Receptors, Opioid
Receptors, Opioid, mu - agonists
Receptors, Opioid, mu - antagonists & inhibitors
Receptors, Opioid, mu - physiology
Sciatic Nerve - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of new NOP receptor agonists and antagonists in the rat chronic constriction injury model was investigated. Intraperitoneally administered NOP receptor agonist SR14150 and antagonists SR16430 and SR14148, had no effect on mechanical allodynia when given alone. The nonselective NOP/mu-opioid receptor agonist SR16435, however, produced an anti-allodynic response, similar to morphine and reversible by naloxone. Notably, co-administration of the NOP receptor antagonists potentiated the anti-allodynic activity of both morphine and SR16435. Increased levels of the NOP receptor are implicated in the reduced efficacy of morphine in neuropathic pain. Our results suggest the utility of NOP receptor antagonists for potentiating opioid efficacy in chronic pain.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2009.03.019